Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, Alpha Diallo, Julien Poissy et al.|Critical Care|2023Cited by 47
Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 TrialMarius Trøseid, Alpha Diallo, José Ramón Arribas et al.|SSRN Electronic Journal|2022Cited by 1